The China-based e-commerce company established its place at the internet's head table with an IPO set to close at $25bn, showing the value of strategic investment.

The Pharmstandard-backed pharmaceutical company is seeking to raise the cash in an IPO four months after it closed part of a $45m series D round.

The Novartis-backed pharmaceutical company will use the proceeds to fund pivotal tests for its prostate cancer drug.

The cancer drug developer, which counts Novo Nordisk among its shareholders, floated below its range, but issued a larger number of shares than expected.

Kolltan, which is backed by Purdue Pharma and Gilead Sciences, will use the proceeds to advance its candidates through early-stage clinical trials.

The car rental company is one of several cornerstone investors that will invest $30m as the China-based company seeks $467m from a Hong Kong initial public offering.

The pharmaceutical company, which is developing treatments for disorders including neuropathic pain and Crohn's Disease, is backed by investors including AbbVie.

The offering will value the corporate-backed incubator and venture fund at approximately $6.45bn.

The e-commerce company is planning to launch the largest IPO ever, putting Yahoo in line to earn $8bn.

ReWalk Robotics, backed by motor technology producer Yaskawa Electric, has updated the terms of its IPO and plans to sell 3.35 million of its shares to raise up to $53.6m.